جست‌وجوی استاد و پژوهشگر

• Nuclear Magnetic Resonance (NMR)
• In vivo imaging
• MRI pulse sequence development
• +۷ مورد دیگر

Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.

• Health services research
• Implementation science
• Patient-reported outcomes
• +۶ مورد دیگر

Rachel Hess, MD, MS is Professor of Population Health Sciences and Internal Medicine and Associate Vice President for Research-Health Sciences at the University of Utah Schools of the Health Sciences. She co-directs the Utah Clinical and Translational Science Institute and was founding Chief of the Division of Health System Innovation and Research (2014-2022). A board-certified General Internist and internationally recognized health-services researcher, she focuses on translating evidence into practice through health-information technology and patient-centered outcomes. Education & Training MD – University of New Mexico School of Medicine MS Clinical Research – University of Pittsburgh Fellowship – General Internal Medicine & Women’s Health, University of Pittsburgh / VA Pittsburgh Medical Center Chief Residency – Internal Medicine, Western Pennsylvania Hospital Residency – Internal Medicine, Temple University Hospital BA Mathematics – Washington University in St. Louis Research Focus Dr Hess’s program is dedicated to improving patient-centered outcomes by leveraging implementation science, health-information technology, and patient-reported measures. Her work spans: Design and nationwide deployment of EHR-integrated clinical decision support for cancer genetics, lung-cancer screening, heart-failure management, and antibiotic stewardship. Large multi-site pragmatic trials (ADAPTABLE, RECOVER, BRIDGE, MAINTAIN) examining effectiveness, equity, and scalability of digital-health interventions. Women’s health across the lifespan, including studies on menopause, sexual function, and post-COVID sequelae. Advanced analytics linking patient-reported outcomes (PROs) with healthcare utilization and cost. Scientific Awards & Recognition Board Certification, American Board of Internal Medicine (Internal Medicine) Leadership of NIH RECOVER Consortium adult cohort—one of the largest studies of Long COVID worldwide Principal investigator on >$50 million in federal and foundation funding (PCORI, NHLBI, NCI, AHRQ, CDC) Leadership & Service As Associate Vice President for Research she sets strategic priorities for the Schools of Medicine, Nursing, Pharmacy, Dentistry, and Health. She co-chairs the Utah Clinical and Translational Science Institute, oversees campus-wide clinical-trials infrastructure, and mentors interdisciplinary teams spanning informatics, behavioral science, epidemiology, and clinical medicine. Laboratories & Teams Dr Hess leads the Health System Innovation and Research (HSIR) group—an interdisciplinary unit of data scientists, implementation researchers, clinicians, and patient partners—dedicated to rapid-cycle testing and national scale-up of digital-health solutions.

Charlotte Kloftمشاهده پروفایل

استاد

• Pharmacometrics
• Computational Disease Modeling
• Therapeutic Drug Monitoring
• +۶ مورد دیگر

Professor Charlotte Kloft is Head of the Department of Clinical Pharmacy & Biochemistry at the Institute of Pharmacy, Free University of Berlin since 2011, and spokesperson for the interdisciplinary Graduate Research Training Program PharMetrX 'Pharmacometrics and Computational Disease Modelling' since 2008. She previously served as Professor and Head of the Department of Clinical Pharmacy at Martin-Luther-University Halle-Wittenberg (2005-2011) and as Scientific Assistant/Senior Assistant at Freie Universität Berlin (1999-2005). Her academic credentials include a habilitation in Clinical Pharmacy from Freie Universität Berlin (2003) and a Dr. rer. nat. (summa cum laude) from the same institution (1997). She earned her license as a pharmacist in 1992 after completing pharmacy studies at Johannes Gutenberg-University, Mainz (1987-1991). Professor Kloft's research focuses on pharmacometrics, computational disease modeling, and therapeutic drug monitoring across multiple therapeutic areas. Her work bridges pharmaceutical sciences with clinical practice, with particular emphasis on personalized dosing strategies for oncology, antimicrobial resistance, and inflammatory bowel diseases. She has pioneered research in optimizing drug dosing through pharmacokinetic/pharmacodynamic modeling, with applications in both antibiotic and cancer therapies. Her recent publications demonstrate a strong evolution toward integrating advanced computational approaches with clinical pharmacology, including machine learning applications in pharmacometrics, personalized dosing strategies for biologics during pregnancy, and developing nationwide infrastructure for therapeutic drug monitoring in cancer therapy through the ON-TARGET study. Academic Center of Excellence of Pharsight (now Certara), USA (since 2000) Habilitationsreisestipendium of Dr. August and Dr. Anni Lesmüller-Stiftung (2002) Ernst-Reuter-Preis of Ernst-Reuter-Gesellschaft (1998) Joachim-Tiburtius-Preis of Berlin Senate (1998) Young Investigator Award of EORTC-PAMM (1997) Professor Kloft has successfully supervised numerous doctoral students whose research spans diverse areas including CAR-T cell therapy, antimicrobial resistance, inflammatory bowel disease treatment optimization, and pharmacokinetic modeling of novel therapeutic agents. Her research group has secured significant funding for projects including GlobalResist, ON-TARGET, ABIMMUNE, COMBINATORIALS, and TAIN. She leads a vibrant research ecosystem at the Free University of Berlin with strong collaborations across Europe and internationally, maintaining state-of-the-art laboratory facilities including Biosafety Level 2 certified labs for infectious disease research.

Mark Greenwaldمشاهده پروفایل

استاد

• Substance Abuse Research
• Opioid Use Disorder
• Addiction Neuroscience
• +۵ مورد دیگر

Mark Greenwald is a Professor and Associate Chair for Research in the Department of Psychiatry at Wayne State University School of Medicine. His work focuses on substance abuse research, particularly on pharmacological and neurobiological mechanisms of opioid and other substance use disorders. With numerous publications and significant contributions to the field of addiction medicine, Dr. Greenwald leads the Substance Abuse Research Division and collaborates extensively with researchers across multiple disciplines to advance understanding and treatment of addiction. Dr. Greenwald's research spans multiple domains of addiction science, with particular expertise in pharmacological determinants of drug-seeking behavior , neuroimaging of addiction-related neural processes , and development of novel treatment approaches for opioid use disorder . His work employs advanced methodologies including PET imaging of opioid and dopamine systems, fMRI, EEG, and 1H spectroscopy to investigate the biological underpinnings of addiction. A significant portion of his research focuses on optimizing buprenorphine treatment protocols and understanding individual differences in treatment response. Dr. Greenwald's recent publications reveal a strong focus on advancing precision medicine approaches for opioid use disorder, with particular attention to pharmacogenetic factors, neuroimaging biomarkers, and individualized treatment protocols. His work increasingly integrates neurobiological, psychological, and social determinants of addiction to develop comprehensive treatment models. Notably, his research bridges basic science with clinical applications, translating neuropharmacological insights into improved treatment strategies for patients struggling with opioid addiction. National Institutes of Health awarded Wayne State $1.19 million for addiction neuroscience predoctoral training Contributed to $16.6 million drug development project for treatment of opioid use disorder Provost's Social & Behavioral Determinants of Health Steering Committee member Led clinical trial proving neurostimulation device to treat opioid use disorder is effective As Associate Chair for Research, Dr. Greenwald oversees research initiatives within the Department of Psychiatry and mentors junior faculty and research staff. His substantial NIH-funded research program supports multiple clinical trials investigating novel approaches to treating opioid use disorder. Dr. Greenwald has secured significant grant funding for projects including a $1.19 million NIH award for addiction neuroscience predoctoral training and contributions to a $16.6 million drug development project for opioid use disorder treatment. His leadership extends to serving on the Provost's Social & Behavioral Determinants of Health Steering Committee. Dr. Greenwald leads the Substance Abuse Research Division at Wayne State University, which employs a multidisciplinary approach to addiction research. His team collaborates with key researchers including Leslie Lundahl, David Ledgerwood, and Cynthia Arfken (focusing on substance use disorders and HIV/AIDS); Jeffrey Stanley (specializing in 1H spectroscopy); Vaibhav Diwadkar (fMRI, learning/memory); Sylvie Naar-King and Paul Burghardt (stress, physical activity and obesity); Terrance Albrecht, Ann Schwartz and Jennifer Beebe-Dimmer (chemotherapy-induced peripheral neuropathy); Timothy Roehrs (Henry Ford: EEG, sleep, pain); and Margit Burmeister (University of Michigan: pharmacogenetics).

Christopher D. Abrahamمشاهده پروفایل

دانشیار

• Radiation Oncology
• Neuro-Oncology
• Brain Tumor Treatment
• +۴ مورد دیگر

Christopher D. Abraham, MD is an Associate Professor of Radiation Oncology and Associate Professor of Medicine at Washington University School of Medicine in St. Louis. He is affiliated with the Siteman Cancer Center, Brain Tumor Center, and Institute of Clinical and Translational Sciences (ICTS). Dr. Abraham practices at multiple locations including the Center for Advanced Medicine Radiation Oncology Center, Barnes-Jewish West County Hospital, and Siteman Cancer Center – North County. His clinical work focuses on radiation oncology with expertise in treating brain tumors and other cancers. Dr. Abraham completed his Medical Degree at Saint Louis University School of Medicine in 2011 and his Residency in Radiation Oncology at Barnes-Jewish Hospital and Washington University School of Medicine in 2016. He earned his BS in Radiologic Science from the Medical College of Georgia in 2004. Dr. Abraham's research focuses on advancing radiation therapy techniques, particularly in stereotactic radiosurgery for brain metastases, hippocampal-avoidance whole brain radiation therapy, and innovative approaches for glioblastoma treatment. His work demonstrates a strong emphasis on optimizing radiation delivery while minimizing neurocognitive side effects. He has pioneered simulation-free radiation therapy techniques that expedite treatment planning, particularly for palliative care patients. His research also explores the integration of AI and large language models in radiation oncology workflows and insurance appeals processes. Analysis of Dr. Abraham's recent publications reveals a clear research trajectory focused on improving precision in radiation therapy for brain tumors, with particular attention to hippocampal protection, adaptive planning techniques, and combined modality approaches. His work spans clinical trials, technical innovations in treatment planning, and translational research connecting imaging with treatment outcomes. The increasing citation counts of his work, particularly his 2023 paper on simulation-free radiation therapy which has 34 citations, demonstrates growing impact in the field. While specific awards are not listed in the provided information, Dr. Abraham's work has accumulated 536 citations according to Scopus metrics, indicating significant scholarly impact. His research has been referenced in clinical guidelines and policy sources, demonstrating translational relevance to clinical practice. Dr. Abraham actively collaborates with multidisciplinary teams including neurosurgeons, medical oncologists, and physicists. His work on the NRG Oncology/RTOG 0631 trial demonstrates involvement in large cooperative group studies. He has contributed to efforts examining insurance policy adherence to radiation oncology guidelines, showing engagement with healthcare systems issues. As a key member of the Brain Tumor Center at Siteman Cancer Center, Dr. Abraham participates in comprehensive brain tumor care teams that integrate surgical, medical, and radiation oncology approaches. His work with the Institute of Clinical and Translational Sciences highlights his commitment to translating research findings into clinical practice. Current research directions include exploring simulation-free radiation therapy techniques, optimizing hippocampal-sparing approaches, and investigating novel combinations of radiation with immunotherapies.

Mathangi Gopalakrishnanمشاهده پروفایل

دانشیار

• Pharmacometrics
• Precision Therapeutics
• Predictive Analytics
• +۹ مورد دیگر

Mathangi Gopalakrishnan, PhD, MPharm, is an Associate Professor in the Department of Practice, Science, and Health Outcomes Research at the University of Maryland School of Pharmacy. She is actively engaged in research, mentoring, and academic scholarship, with a focus on quantitative clinical pharmacology and data-driven therapeutic optimization. Education: PhD, Statistics, University of Maryland, Baltimore County MS, Statistics, University of Maryland, Baltimore County MPharm, Birla Institute of Technology & Science, Pilani, Rajasthan, India BPharmacy (Honors), Birla Institute of Technology & Science, Pilani, Rajasthan, India Her research interests center on pharmacometrics, precision therapeutics, predictive analytics, real-world data, and drug development . She integrates principles of clinical pharmacology, advanced frequentist and Bayesian statistical methods, and artificial intelligence/machine learning to enhance patient outcomes, particularly among vulnerable populations. Her lab's work includes designing prospective clinical pharmacokinetic trials for anti-epileptics and antimicrobials in patients on continuous renal replacement therapy, leveraging real-world data from electronic health records to optimize dosing in neonatal opioid withdrawal syndrome and pediatric anticoagulation, and developing models for disease progression in conditions like schizophrenia and binge-eating disorders. The trends in her recent publications reflect a consistent focus on model-informed precision dosing, real-world evidence generation, pharmacokinetic-pharmacodynamic (PK/PD) modeling in special populations, and methodological innovation in clinical trial design . Her work spans diverse therapeutic areas including critical care, neonatology, psychiatry, and maternal health, demonstrating a broad impact of quantitative pharmacology. Dr. Gopalakrishnan is accepting applications for postdoctoral positions in pharmacometrics at the Center for Translational Medicine, indicating active research funding and team leadership. Her collaborations extend to academic medical institutions nationwide, underscoring her role in multi-center research initiatives. She is involved in collaborative research with academic medical institutions across the country and has presented her work at major conferences including the Joint Statistical Meetings (JSM) and the American Conference on Pharmacometrics (ACoP).

• Research Methods
• Pathology
• Molecular Biology
• +۷ مورد دیگر

Dr. Faith Kwa is a Senior Lecturer and Course Director for the seven Bachelor of Health Science degrees at Swinburne University of Technology's School of Health Sciences. Her teaching interests include Research Methods, Pathology, and Molecular Biology. She leads the Drug Discovery for Chronic Diseases Laboratory and has been recognized as one of Australia's leading educators, receiving the 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching. Her educational background includes: Doctor of Philosophy from The University of Melbourne, Australia Graduate Certificate in Tertiary Teaching and Learning from RMIT University, Australia Bachelor of Biomedical Science from The University of Melbourne, Australia Bachelor of Science (Honours - First Class) from The University of Melbourne, Australia Fellow of the Higher Education Academy, United Kingdom (2020-present) Dr. Kwa is a molecular biologist whose research focuses on drug discovery for chronic diseases, particularly in the areas of epigenetic medicine, molecular mechanisms of action, and chronic disease prevention and management. Her laboratory has made significant contributions to understanding treatment strategies for leukemia, posterior eye diseases, and Friedreich's ataxia using natural compounds with epigenetic properties. She has made novel observations regarding low doses of epigenetic modifiers in combination therapies that potentiate cytotoxicity in leukemia cells resistant to conventional chemotherapeutic drugs. Her work with sulforaphane (a broccoli-derived compound) has shown therapeutic benefits across multiple disease models, particularly for neurodegenerative and ocular conditions. Analysis of her recent publications reveals a strong focus on neurodegenerative disorders (particularly Friedreich's ataxia), ophthalmic diseases, and molecular approaches to disease treatment. Her work consistently bridges basic science with clinical applications, often examining epigenetic mechanisms and oxidative stress pathways. A recurring theme across her research is the therapeutic potential of natural compounds like sulforaphane, which appears in multiple disease contexts from mitochondrial myopathies to posterior eye diseases. Her scientific recognition includes: 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching 2023 Vice-chancellor's Award for Teaching Excellence (Higher Education - Individual) 2023 School of Health Science Teaching Excellence Award Fellow of the Higher Education Academy in the UK 18 other teaching accolades throughout her academic career Dr. Kwa supervises PhD and Master's students in areas related to molecular mechanisms of disease and therapeutic interventions. She has coordinated and taught eleven different subjects with student numbers ranging from 20 to over 300. As a Chief Investigator, she has secured various learning and teaching grants from Australian universities. Currently, she holds funding for 'Pre-clinical investigations on sulforaphane to advance the cure for Friedreich's ataxia' from the University of Melbourne (2022-2025). She is passionate about developing pedagogical methods to enhance teaching and learning environments and has received positive student feedback throughout her career. Dr. Kwa leads the Drug Discovery for Chronic Diseases Laboratory, where her team investigates potential treatments for various chronic disorders. She also serves as the Swinburne Women Academic Network Leader in the Career Development Team, where she develops programs supporting women academics in progressing their careers. Her laboratory work utilizes pre-clinical disease models to evaluate therapeutic approaches, with a particular emphasis on targeted therapies with superior efficacy for treating human diseases.

Hannah Claphamمشاهده پروفایل

استادیار

• Infectious Disease Dynamics and Control
• Vaccination Impact Analysis
• Dengue Epidemiology
• +۳ مورد دیگر

Hannah Clapham is an Assistant Professor and Programme Leader (Infectious Diseases) at the Saw Swee Hock School of Public Health, National University of Singapore. Her research focuses on infectious disease dynamics, vaccination impact, and epidemiology of dengue and Japanese encephalitis. She holds a PhD in Disease Dynamics from Imperial College London and has held roles including Head of the Mathematical Modelling Group at the Oxford University Clinical Research Unit in Vietnam. Her work integrates mathematical models with public health policy to address global health challenges, particularly in resource-limited settings. Education: BA Hons Mathematics, University of Oxford (2004-2007) MSc Modern Epidemiology, Imperial College London (2008-2009) PhD Disease Dynamics, Imperial College London (2009-2013) Research Interests: Her research emphasizes quantitative approaches to understand disease transmission, assess vaccine effectiveness, and inform policy. Key themes include: Mathematical modeling of dengue and arbovirus outbreaks Impact of vaccination strategies on disease control Serological data analysis to infer infection history Public health responses to pandemics (e.g., SARS-CoV-2) Media Contributions: Dr. Clapham frequently engages with media to explain public health issues, including commentaries on Singapore’s dengue outbreaks, pandemic preparedness, and vaccination strategies for Channel NewsAsia , The Straits Times , and others. Grants & Collaborations: Her career includes leadership in interdisciplinary projects, such as the Vaccine Impact Modelling Consortium and studies on pathogen genomics in Southeast Asia. She collaborates with global health organizations to translate research into actionable policies.

Jun J. Yangمشاهده پروفایل

استاد

• Pharmacogenomics
• Childhood Cancer
• Leukemia Treatment
• +۴ مورد دیگر

Jun J. Yang, PhD, is a Professor and Vice-Chair in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children’s Research Hospital. He holds an Endowed Chair in Pharmacogenomics and is affiliated with the Comprehensive Cancer Center and St. Jude Graduate School of Biomedical Sciences. His research focuses on understanding the genetic basis of inter-patient variability in anticancer drug responses, particularly in pediatric leukemia. Key areas include pharmacogenomics of anti-leukemia drug toxicities, genomics of drug sensitivity/resistance, and leveraging genetic insights to develop precision therapies. Dr. Yang earned his PhD from Purdue University and has been continuously funded by the NIH since 2011. He leads the Yang Lab, which employs genomic and systems pharmacology approaches to decode leukemia heterogeneity. Notable achievements include identifying genetic polymorphisms in NUDT15 that predict thiopurine toxicity, leading to FDA label changes, and discovering biomarkers for drug response in T-cell ALL. He has received prestigious awards, including the 2024 Mentor of the Year from St. Jude and the 2023 Waun Ki Hong Award. His work emphasizes global collaborations, particularly in studying diverse pediatric leukemia cohorts. Current projects include developing biomarker-informed clinical trials, understanding chemotherapy-induced liver toxicity mechanisms, and identifying genetic risk factors for leukemia susceptibility. Education: PhD, Purdue University (2006) Affiliations: Hematological Malignancies Program, St. Jude Postdoctoral Leadership Council Grants: NIH, V Foundation

Ursula Klingmüllerمشاهده پروفایل

استاد

• Systems Biology
• Signal Transduction
• Molecular Biology
• +۵ مورد دیگر

Prof. Dr. Ursula Klingmüller is a Professor at Ruprecht-Karls-Universität Heidelberg and Head of the Division Systems Biology of Signal Transduction (B200) at the German Cancer Research Center (DKFZ) in Heidelberg since 2007. She holds a Venia Legendi in Cell Biology (Heidelberg University, 2004) and Molecular Biology & Genetics (University of Freiburg, 2000). Her career spans leadership roles in systems biology, integrating computational and experimental approaches to understand cellular signaling networks in cancer and other diseases. Education: Diploma in Molecular Biology, Cell Biology, and Virology (University of Heidelberg, 1988) Bachelor of Science (University of Bayreuth, 1985) Doctoral Thesis in Molecular Biology (Heidelberg University, 1992) Research Interests focus on systems biology approaches to signal transduction, particularly the JAK2/STAT5, AKT/ERK, and TGF-β pathways, their roles in cell proliferation, cancer invasion, and dynamic threshold regulation. Her work emphasizes computational modeling of signaling networks and their integration with clinical applications in precision medicine. Key Scientific Contributions include elucidating the context-specific dynamics of ERK phosphorylation, defining the regulatory roles of BAMBI in TGF-β signaling, and advancing personalized dose prediction models for erythropoietin therapies. Her publications reflect interdisciplinary research bridging molecular mechanisms with quantitative modeling. Scientific Awards: FEBS Anniversary Prize (1997) DAAD-Fellowship (1986) DFG-Research Fellowship (1993-1994) Election to the German Ethics Council (2016) Labs & Teams include the Systems Biology of Signal Transduction division at DKFZ, collaborations with the German Cancer Research Center, and leadership in the Master Program Molecular Biosciences at Heidelberg University. She also serves on editorial boards, including as Associate Editor for Nature Systems Biology and Applications , and chairs the Executive Women's Initiative at DKFZ.

Francesca Ievaمشاهده پروفایل

دانشیار

• Biostatistics
• Health Data Science
• Statistical Learning
• +۵ مورد دیگر

Francesca Ieva serves as Associate Head of the Health Data Science Centre at Human Technopole and Associate Professor of Statistics at the Politecnico di Milano, where she leads the MOX - Modeling and Scientific Computing laboratory within the Department of Mathematics. She also co-leads the Di Angelantonio & Ieva Group, a collaborative research team focused on integrating molecular data with clinical information to advance precision medicine. Dr. Ieva received her PhD in Mathematical Models and Methods for Engineering in 2012. Her academic journey has positioned her at the forefront of health data science, bridging statistical methodology with biomedical applications. Her research focuses on statistical learning in biomedical sciences, with particular emphasis on developing advanced models for integrating complex clinical data to inform predictions in clinical decision-making. Francesca's work spans multiple domains including: Development of novel survival analysis techniques for healthcare applications Integration of DNA methylation data for cardiovascular risk prediction Application of machine learning to clinical pathway analysis in mental health Innovative approaches to polygenic risk scoring incorporating SNP interactions Development of radiomics models for cancer prognosis and treatment response Analysis of Dr. Ieva's recent publications reveals a strong trend toward federated learning approaches in healthcare data analysis, reflecting growing concerns about data privacy while maintaining analytical power. Her work increasingly integrates multiple data types (genomic, epigenetic, imaging, and clinical records) to create more comprehensive patient profiles for precision medicine applications. A notable pattern is her focus on translating complex statistical models into clinically actionable tools that can directly inform patient care and healthcare policy decisions. As Associate Head of the Health Data Science Centre at Human Technopole, Dr. Ieva oversees a research group comprising epidemiologists, statisticians, and data scientists working collaboratively to bridge the gap between genotype and phenotype. The Di Angelantonio & Ieva Group develops innovative studies that integrate biomolecular data with medical records, imaging, and portable medical device data. Her team utilizes both existing healthcare data and newly generated population-based studies, applying novel analytical methods that integrate clinical epidemiology with health research to improve data interpretation. Dr. Ieva actively mentors several PhD students including Andrea Lampis, Katherine Marie Logan, Alessia Mapelli, Michela Carlotta Massi, and Andrea Mario Vergani. Her research has been supported by collaborations with major healthcare institutions and likely receives funding from research councils and health technology initiatives, though specific grant details are not provided in the available information.

Varun Vaidyaمشاهده پروفایل

استاد

• Pharmacoeconomics
• Health Outcomes Research
• Real-World Evidence
• +۳ مورد دیگر

Dr. Varun Vaidya is a Professor and the Director of B.S.P.S. Pharmacy Administration Program and M.S.P.S. Health Outcomes and Socioeconomic Sciences program in the Department of Pharmacy Practice at the University of Toledo College of Pharmacy and Pharmaceutical Sciences. He serves as the faculty advisor to the UT-ISPOR chapter and holds significant roles in national organizations including the Pharmacy Quality Alliance (PQA) Data & Interoperability Advisory Group (DIAG), ISPOR, APhA, and AACP. Dr. Vaidya's educational background includes: Ph.D. in Pharmacoeconomics from University of Tennessee, Memphis (2009) B.Pharm. from Bharati Vidyapeeth, India (2002) Certification in Measurement, Design and Analysis Methods for Health Outcomes Research from Harvard School of Public Health (2010) His research program centers on quantitative assessment of health outcomes related to medication use, with particular expertise in real-world evidence (RWE) studies that inform value-based decision making and outcomes-driven healthcare delivery. Dr. Vaidya has extensive experience with claims databases including Optum, GE, MarketScan, Truven, and Clinical Practice Research Datalink (CPRD) U.K., as well as U.S. national databases such as Medical Expenditure Panel Survey (MEPS), Behavioral Risk Factor Surveillance Survey (BRFSS), and National Health and Nutrition Examination Survey (NHANES). His publication record demonstrates a strong focus on pharmacoeconomics across multiple therapeutic areas including oncology (particularly lung cancer and myelofibrosis), diabetes management, mental health, opioid use disorder, and medication adherence patterns. His work frequently examines medication utilization patterns, healthcare costs, treatment effectiveness, and the impact of social determinants on health outcomes. Dr. Vaidya actively contributes to the academic and professional community through his role as program director, faculty advisor, and national organization participation. He is frequently invited to speak at national and international venues and provides expertise to media outlets on prescription drug pricing and pharmaceutical policy issues, having featured in news segments and authored Op-Ed articles on these topics.

• Pharmacokinetics/Pharmacodynamics (PKPD) Modeling
• Translational Research
• Antibiotic Resistance
• +۷ مورد دیگر

Lena Friberg is a Professor at Uppsala University's Department of of Pharmacy (Pharmacokinetics and Pharmacodynamics) since 2021, previously holding the same title in Pharmacometrics (2014-2021). With over 190 peer-reviewed publications and an h-index of 56, her research focuses on translational PKPD modeling for dose optimization in oncology and infectious diseases. Developed frameworks for preclinical-to-clinical translation Work spans cancer chemotherapy, antibiotic resistance, and drug combinations Utilizes non-linear mixed effects modeling and physiologically-based approaches Scientific Awards : Giorgio Segré Prize (EUFEPS) Innovation Award (ISoP) ISoP Fellow Vinnova/BioSweden Key Scientist She supervises 9 PhD students, mentors postdocs, and holds grants from Swedish Research Council, Swedish Cancer Society, EU-IMI2, and Marie Skłodowska-Curie ITN. Her work facilitates drug development transitions while considering therapeutic and adverse effects.

• Clinical Pharmacology
• Pharmacogenomics
• Pharmacometrics
• +۷ مورد دیگر

Associate Professor Sophie Stocker is affiliated with the Sydney Pharmacy School (University of Sydney), St Vincent’s Hospital (Honorary Senior Hospital Scientist in Clinical Pharmacology and Toxicology), and the Garvan Medical Research Institute . She also serves as an Adjunct Senior Lecturer at the St Vincent’s Clinical School, University of New South Wales. Research Focus: Her work spans clinical pharmacology , pharmacogenomics , pharmacometrics , and therapeutic drug monitoring (TDM) . Key areas include optimizing diabetes therapies through metformin pharmacogenomics, managing gout via urate-lowering strategies, and improving antimicrobial dosing in critically ill patients. Recent Trends: 2025 publications highlight her leadership in Bayesian model selection for antibiotic precision dosing Saliva-based TDM innovations Pharmacogenomic tools for allopurinol and clopidogrel Evaluating SGLT2 inhibitors in chronic kidney disease Global standards for antifungal TDM Scientific Awards: Victor Armstrong Young Investigator Award (2022) Emerging Leader Award (2020) CERTARA Young Investigator Award (2020) St Vincent's Rising Star (2018) ASCEPT Presidential Trainee Award (2013) Supervision: She mentors research students working on projects such as voriconazole TDM strategies , saliva-based tuberculosis monitoring , and CYP2C19-guided antiplatelet therapy . International Links: Collaborates with institutions in Germany (University of Hamburg) and New Zealand (University of Otago) on projects like model-informed precision dosing and gout management.

• Infectious Diseases Pharmacotherapy
• Antimicrobial Pharmacokinetics/Pharmacodynamics
• Multidrug-Resistant Bacteria
• +۳ مورد دیگر

Ashlan J. Kunz Coyne, PharmD, MPH is an Assistant Professor in the Department of Pharmacy Practice & Science at the University of Kentucky, specializing in infectious diseases pharmacy with a focus on antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) and multidrug-resistant bacteria. Education & Training Doctor of Pharmacy (PharmD), University of Florida PGY1 Pharmacy Practice Residency, UF Health Jacksonville PGY2 Infectious Disease Pharmacy Practice Residency, UF Health Jacksonville Master of Public Health (MPH), Wayne State University ACCP peer-reviewed PK/PD & Health Outcomes Pharmacotherapy Fellowship, Wayne State University Research Focus Dr. Kunz Coyne’s research leverages precision PK/PD modeling and multi-omics approaches to optimize antimicrobial regimens against resistant pathogens. Her work spans: Phage–antibiotic synergy against MRSA, Pseudomonas aeruginosa , and Enterococcus spp. Clinical outcomes of novel β-lactam/β-lactamase inhibitors (ceftazidime-avibactam, cefiderocol, eravacycline) Obesity-related PK alterations and their impact on antimicrobial efficacy Penicillin allergy de-labeling strategies in outpatient settings Antimicrobial stewardship aided by rapid molecular diagnostics Scientific Recognition National Institutes of Health Loan Repayment Program (NIH LRP) Award Grants & Future Directions Supported by the NIH LRP, Dr. Kunz Coyne aims to expand translational PK/PD studies that integrate clinical data with in-vitro and ex-vivo models to inform evidence-based dosing for high-risk populations, including immunocompromised and critically ill patients. Laboratory & Teams She collaborates closely with interdisciplinary teams across the University of Kentucky College of Pharmacy, infectious diseases divisions, and external multicenter networks to conduct prospective cohort studies and real-world evidence analyses.